Nordic Nanovector Capital Markets Day 2015: Reiterates Its Commitment To Becoming A Significant Player In Oncology And Hematology

OSLO, Norway--(BUSINESS WIRE)--On 17 November 2015, Nordic Nanovector ASA (OSE:NANO) hosted its first Capital Markets Day in Oslo to provide investors, analysts and press with the opportunity to learn more about the Company’s corporate strategy, its lead product Betalutin®, a potential new treatment for non-Hodgkin’s lymphoma (NHL), its development and commercialisation plans, as well as future opportunities for value creation.

Help employers find you! Check out all the jobs and post your resume.